

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Tahereh Tabatabaie
Yashige Kotake

Serial No.: 09/852,587

Filed: May 10, 2001

For: PREVENTION OF INSULIN-
DEPENDENT DIABETES,
COMPLICATIONS THEREOF, OR
ALLOGRAFT REFECTION BY
INHIBITION OF CYCLOOXYGENASE-2
ACTIVITY

Group Art Unit: 1640


Examiner: Unknown

Atty. Dkt. No.: OMRP:008US

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 15, 2002	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112237/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 15, 2002



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

OMRF:008US

Serial No.

09/852,587

Applicant

Tahereh Tabatabaie

Yashige Kotake

Filing Date:

May 10, 2001

Group:

1640

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

RECEIVED

TECH CENTER 1600/2900

JUL 23 2002

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,939,069	8/17/99	Clare-Salzler	424	184.1	8/23/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 00/00192	1/6/00	PCT			
	B2	WO 97/29775	8/21/97	PCT			
	B3	WO 97/29776	8/21/97	PCT			
	B4	WO 98/19649	5/14/98	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bedoya <i>et al.</i> , "Pyrrolidine dithiocarbamate prevents IL-1 induced nitric oxide synthase mRNA, but not superoxide dismutase mRNA, in insulin producing cells," <i>Biochemical and Biophysical Research Communication</i> , 210(3):816-822, 1995.
	C2	Cooper <i>et al.</i> , "Myocardial nuclear factor-kB activity and nitric oxide production in rejecting cardiac allografts," <i>Transplantation</i> , 66:838-844, 1998.
	C3	Crespo <i>et al.</i> , "Role of COX-II in the genesis of endothelial dysfunction in STZ-diabetic rats," <i>FASEB Journal</i> , 15(4): A467, 2001.
	C4	Flodstrom <i>et al.</i> , "Cytokines activate the nuclear factor kB (NF-kB) and induces nitric oxide production in human pancreatic islets," <i>FEBS Letters</i> , 385:4-6, 1996.
	C5	Huynh <i>et al.</i> , "Control of intimal hyperplasia by local modulations of NF-kB activity in experimental vein grafts," <i>American College of Surgeons</i> , 48:441-444, 1997.
	C6	Komers <i>et al.</i> , "Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes," <i>J. Clin Invest.</i> , 107:889-898, 2001.
	C7	Ross <i>et al.</i> , "Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor-kB," <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> , 279:L528-L536, 2000.


25186870.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)



List of Patents and Publications of Applicant(s)

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

OMRF:008US

Serial No.

09/852,587

Applicant

Tahereh Tabatabaie

Yashige Kotake

Filing Date:

May 10, 2001

Group:

1640

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Tabatabaie <i>et al.</i> , "COX-2 inhibition prevents insulin-dependent diabetes in mice," <i>Free Radical Biology & Medicine</i> , 29 (Supp. 1): S109, 2000.

25186870.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900